On Monday, Facebook, Inc. (NASDAQ:FB)’s shares inclined 1.18% to $83.01, as according to Forbes, a social networking company last month rolled out new features aimed at giving friends more reasons to chat. With Messenger Platform, developers can now build apps for the service, in turn, giving users more ways to share media without leaving their chat screens. Facebook featured about 40 apps in the Messenger launch, counting two from video startup Joya: FlipLip and Cleo.
Joya’s latest two apps, which let users record videos for friends with characters, voices or wacky filters, emphasize humor and ease of use, features that could assist propel Facebook’s engagement with young audiences. Facebook’s endorsement of the video startup capitalizes on trends that young smartphone owners watch video on their devices much more often than older age groups do, a Pew study showed this month. Video tools are becoming increasingly important to the site as it tries to retain and grow young users’ interest.
Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications.
Zions Bancorporation (NASDAQ:ZION)’s shares gained 1.17% to $27.65, during the last trading session on Monday, as a financial holding company, declared that it will report its first quarter 2015 earnings results after the NASDAQ close on Monday, April 20, 2015. A conference call discussing the quarterly results will be held at 5:30 p.m. ET on the same day. Forward looking and other material information may be discussed on this conference call.
Media representatives, analysts and the public are invited to listen to the conference call by dialing (253) 237-1247 (domestic and international) and entering the passcode 10432053.
Zions Bancorporation, a financial holding company, provides a range of banking and related services in Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming.
At the end of Monday’s trade, LifeLock, Inc. (NYSE:LOCK)’s shares gained 1.17% to $14.76, as LifeLock will report financial results for the first quarter ended March 31, 2015 after market close on Wednesday, April 29, 2015. The company also declared that it will hold a conference call on the same day at 5:00 PM Eastern Time to talk about its quarterly financial results. The conference call may comprise forward-looking statements.
LifeLock, Inc. provides identity theft protection services for consumers; and consumer risk administration services for enterprises in the United States. It protects consumer subscribers through monitoring identity-related events, such as new account openings and credit-related applications; and enterprise customers through delivering on-demand identity risk, identity authentication, and credit information about consumers.
Finally, Arrowhead Research Corp. (NASDAQ:ARWR), ended its Monday’s trading session with 1.14% gain, and closed at $8.00, as according to TheStreet.com, the biopharmaceutical company declared a new permission from the Food and Drug Administration.
The FDA informed Arrowhead that it can now proceed with a multiple-dose Phase 2b clinical study of ARC-520, the company’s clinical candidate for the treatment of chronic hepatitis B infection, under an investigational new drug (IND) application formerly filed with the FDA, Arrowhead said in a statement.
“This notification from the FDA allows us to start a multiple-dose Phase 2b study of ARC-520, and we are working diligently to get treatment sites up and running,” said Chief Operating Officer and Head of Research and Development Bruce Given, M.D.
“Our aim is to gain site IRB approvals and perform site initiation visits to start recruiting and enrolling patients for this study in about a month,” he continued. “We are also working with various regulatory agencies outside of the United States to initiate additional Phase 2b studies.”
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
